New Delhi, India and Garching near Munich, Germany, 6th March, 2020. B.J Madan & Co and OncoBeta announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in India.
The OncoBeta® tungsten (wolfram)-188/rhenium-188 (W/Re-188) Generators can be used for radiolabeling reactions or directly as a high dose liquid radioactive source. Rhenium-188 (Re-188) is a high energy-emitting radioisotope obtained from the 188W/188Re Generator. Re-188 has shown a high efficiency and value for a variety of therapeutic applications in the nuclear medicine, oncology, and interventional radiology/cardiology areas. Its advantageous physical properties, its potential low cost, and with a long-lived parent make this generator an attractive option for clinical use. The high energy of the emission of Re-188 is particularly well suited for the effective penetration in solid tumors as well as skin cancers. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy today.
“OncoBeta® has been a pioneer in the epidermal radioisotope sector since 2014. We are happy to collaborate with Shannon D. Brown and his team to bring the 188W/188Re Generators to India, which are used for radiolabelling reactions or as a high dose liquid radioactive source. It fills the vacuum of the much needed assurance of Quality & Consistency of Supply of 188Re Generators in India” Said Taranjit Singh, owner of B.J Madan & Co. (picture)
“We are very proud to be the new suppliers of high-quality 188W/188Re Generators for India and to have won a valued distributor with B.J. Madan & Co. securing the next step in our global strategy” said Shannon D. Brown III, CEO and Managing Director of OncoBeta. “Our generators are characterized for having high activity concentrations and elution volumes which can be used for radiolabeling or directly as a high dose liquid radioactive source. As the only organization worldwide presently capable of securing supply for 188W/188Re Generators, we expect to see a fast increase in demand and interest for projects using Rhenium-188 and look forward to supporting new and exciting market developments worldwide.”
About B.J Madan & Co
B J Madan & Co, a family owned proprietorship company, represented by Taranjit Singh, as its 3rd generation entrepreneur, has its base in New Delhi, India. It has been in the field of in manufacturing and marketing of pharmaceuticals & healthcare products, now stretching over 7 decades. B J Madan & Co, with its objective of Targeting Tumours, diversified in the field of Nuclear Medicine In the year 2005, and has successfully introduced Theranostics Molecules in the country, representing the leading radiopharmaceutical & radiochemistry companies, from across the globe
Learn more us at: https://www.bjmadan.com
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a medical device and radiochemical company, specializing in the development and commercialization of state-of-the-art, innovative radioisotope therapies and products utilizing Rhenium-188. OncoBeta® offers an innovative Skin Cancer Therapy targeting non-melanoma skin cancers and produces Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generators for commercial use.
Learn more us at: https://www.oncobeta.com
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of B.J Madan & Co or OncoBeta®’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning B.J Madan & Co or OncoBeta®’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. B.J Madan & Co or OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.